Rokit Healthcare

At a glance

Rokit Healthcare filed 36 disclosures in the last 12 months, including 7 insider, 1 earnings, 1 5% holder and 1 issuance. The most recent key filing was on May 21.

Revenue for 2025 was ₩26.2B, up 100.2% on 2024. Operating margin was 1.7% against -42.5% a year earlier. Debt was 376% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩16.3B and operating loss of ₩15.8B.

The 2025 annual report lists 90 employees with an average tenure of 4 years. Its 4 directors and auditors were paid ₩97M each on average. It paid no cash dividend for 2025. 유석환 and related parties held 24.85% at year end.

From the 2025 annual report

Staff: 90 (52 men, 38 women), of whom 8 on fixed-term contracts. Directors and auditors: 4, paid ₩387M in total.

No cash dividend was paid for 2025.

Largest shareholder

유석환 holds 24.18%; with 7 related parties the group holds 24.85% of common shares at year end (from 31.06% at the start of the year).

Individuals paid ₩500M or more

Auditor: 대성회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary